CSL Behring
As of the edition of 20 October 2026, CSL Behring runs 33 drugs, 19 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 19 |
| Active | 7 |
| Went quiet | 2 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 33 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Progesterone | none listed | 3 |
| Estradiol | Ends 2032 (patent) | 6 |
| Testosterone | none listed | 4 |
| Folic acid | none listed | 0 |
| Human immunoglobulin g | Ended 2015 (orphan exclusivity) | 0 |
| Albumin human | none listed | 0 |
| Methoxy polyethylene glycol-epoetin beta | Ended 2019 (computed from the first US licence) | 1 |
| Fibrinogen, human | Ended 2021 (computed from the first US licence) | 0 |
| .alpha.1-proteinase inhibitor human | Ended 1999 (computed from the first US licence) | 2 |
| Prothrombin complex concentrate | Ended 2025 (computed from the first US licence) | 0 |
| Conestat alfa | Ended 2026 (reference-product exclusivity) | 0 |
| Difelikefalin | Ends 2032 (patent) | 2 |
| Human coagulation factor viii | Ended 1986 (computed from the first US licence) | 0 |
| Antithrombin iii human | Ended 2003 (computed from the first US licence) | 4 |
| Sparsentan | Ends 2031 (exclusivity) | 2 |
| Iron dextran | none listed | 0 |
| Lonoctocog alfa | Ends 2028 (computed from the first US licence) | 0 |
| Albutrepenonacog alfa | Ends 2028 (computed from the first US licence) | 0 |
| Etranacogene dezaparvovec | Ends 2034 (reference-product exclusivity) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where CSL Behring needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 24 trials led
- Blood and lymph: 19 trials led
- Heart and blood vessels: 12 trials led